FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach

The FDA’s expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
source
Sponsor:News technical sponsor
Sponsor:News AI sponsor
Sponsor: AI sponsor
Sponsor: AI sponsor

Leave a Comment

Vélemény, hozzászólás?

Az e-mail címet nem tesszük közzé. A kötelező mezőket * karakterrel jelöltük